A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the Knee | Recruiting
A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the Knee

Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Pain
  • Osteoarthritis
Robert Macnair, PhD
+44 1357 523481
See all trial contact details
Primary Contact Details
Recruiting
Recruitment Status
NCT00954629
Primary Trial ID Number
Summary
The purpose of the study is to demonstrate the superiority of topically administered 2PX versus placebo (vehicle) control in terms of reduction in pain intensity and physical function.
Research Details
  • Primary objective: To demonstrate the superiority of topically administered 2PX versus placebo (vehicle) control in terms of reduction in pain intensity and physical function. Secondary objectives: To prospectively measure other efficacy variables of topically administered 2PX in pain associated with osteoarthritis of the knee. To evaluate the safety and tolerability of topically administered 2PX.
Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Study Type
Interventional
Intervention
Drug : strontium chloride hexahydrate, Drug : Placebo

Study Arm Groups : 2PX, Placebo

Intervention Type
See Interventions above
Primary Outcome Measures
  • The difference between the active and placebo group in the change from Baseline to the assessment after 26 weeks of treatment in the actual WOMAC Osteoarthritis Index LK 3.1 subscale score for pain and physical function.; 26 weeks
Secondary Outcome Measures
  • WOMAC Osteoarthritis Index LK 3.1; total and non-pain subscales:; At Screening, Baseline, Weeks 2, 4, 12, 26 and 27.; Pain intensity will be assessed by asking the question 'What is the level of pain in your target knee right now?; Daily; Patient Global Impression of Change (PGIC); At weeks 12 and 26; Clinician Global Impression of Change (CGIC); At weeks 12 and 26; Use of rescue medication: The number of paracetamol tablets used each day will be recorded.; Daily; Incidence of Disease Flares: The number and extent of flares in osteoarthritis pain of the target knee between active and placebo groups during the course of treatment.; At weeks 2, 4, 12, 26, and 27
Publication(s)
Sorry, this information is not available
Result Reports
This is available on the Clinicaltrials.gov website
Gender
Both
Age Range
40 Years - N/A
Who Can Participate
Patients
Number of Participants
300
Participant Inclusion Criteria
  • Inclusion Criteria:
  • - Male and female out-patients, 40 years or older.
  • - Subjects with documented OA of either one or both knees, as defined by the American
  • College of Rheumatology (ACR) criteria ([Altman R, Asch E, Bloch D, et al (1986)]);
  • i.e.knee pain and at least 3 out of the following 6 criteria in the target joint:
  • - age >50 years
  • - stiffness < 30 minutes
  • - crepitus
  • - bony tenderness
  • - bony enlargement
  • - no palpable warmth
  • - Radiological evidence of joint space narrowing in the target joint within 8 weeks
  • prior to randomisation.
  • - Subjects with chronic, moderate to severe OA pain of the target knee:
  • - present for more than 3 months, and for ≥ 20 days per month.
  • - not controlled by, or intolerant of, oral NSAIDs, paracetamol, COX-2 inhibitors
  • or weak opioids.
  • - intensity at least moderate (i.e., actual WOMAC (pain questions 1-5) ≥ 10) on
  • WOMAC OA index LK 3.1 at Visit 1, in the target knee, as recalled over the last
  • 24 hours.
  • Exclusion Criteria:
  • - Subjects with any moderate to severe pain of other origin (e.g., fibromyalgia) which
  • could confound assessment or self-evaluation of pain due to OA in the target knee.
  • - Subjects with any prosthesis fitted to the target knee.
  • - Subjects requiring treatment with any of the following agents/therapies within the
  • specified periods or at any time during the study are excluded from participation:
  • - Any potent/strong opioid in the 4 weeks prior to randomisation (i.e., an opioid
  • assumed to cause withdrawal symptoms upon abrupt discontinuation).
  • - Any topical or subcutaneously applied analgesic agents (e.g., capsaicin, NSAIDs)
  • applied to the target knee within 7 days prior to randomisation.
  • - Any treatment which could alter the degree or nature of baseline OA pain planned
  • within the study period.
  • - Intra-articular injections of corticosteroids in the target knee within the 2 months
  • prior to randomisation.
  • - Intra-articular injections of hyaluronan in the target knee within 6 months prior to
  • randomisation.
  • - Avascular necrosis in the target knee within 6 months prior to randomisation.
  • - Arthrosynthesis of the target knee within 12 months prior to randomisation.
  • - Arthroscopy of the target knee within 6 months prior to randomisation.
  • - Major trauma to the target knee within 6 months prior to randomisation.
  • - Infection in the target knee within 6 months prior to randomisation.
  • - Subjects who have previously been treated with 2PX.
  • - Subjects who have received an investigational drug or used an investigational device
  • within the 30 days prior to randomisation.
  • - Subjects with a significant psychiatric disorder, in the opinion of the investigator,
  • or subjects receiving strong anti-psychotic medication.
  • - Subjects with documented or suspected alcohol or drug abuse.
  • - Any ongoing or past history of malignant disease within the 5 years immediately prior
  • to randomisation (with the exception of basal cell carcinoma).
  • - Pregnancy or ongoing lactation
  • - Female subjects of childbearing potential unwilling to use adequate contraceptive
  • measures throughout the duration of the study. For the purpose of this study,
  • adequate contraception is defined as:
  • - oral, injected or implanted hormonal methods of contraception; OR
  • - placement of an intrauterine device (IUD) or intrauterine system (IUS); OR
  • - barrier methods of contraception: Condom or occlusive cap (diaphragm or
  • cervical/vault caps) with spermicidal foam/gel/film/cream/suppository Note: Male
  • sterilisation or abstinence are not acceptable methods of birth control and
  • would preclude enrolment in the study.
  • Note: For post-menopausal women: less than 12 months since the last spontaneous menstrual
  • bleeding will exclude the patient unless they are willing to utilise acceptable methods of
  • contraception for the duration of the study.
  • - Male subjects able to conceive, who are unwilling to use barrier methods of
  • contraception throughout the duration of the study
  • - Subjects unable to comply with the study assessments.
Participant Exclusion Criteria
This is in the inclusion criteria above
Trial Location(s)
Manchester
Bradford
Research Site
Blackpool
Research Site
Bolton
Research Site
Stockport
Trial Contact(s)
Primary Trial Contact
Robert Macnair, PhD
bob.macnair@smerud.com
+44 1357 523481
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Finland, Poland, Russian Federation, United Kingdom
Scientific Title
A 26 Week Placebo-controlled, Randomised, Double-blind, Parallel Group Study of the Efficacy and Safety of 2PX (Topical Strontium Chloride Hexahydrate) in Patients With Pain Due to Osteoarthritis of the Knee
EudraCT Number
Not available for this trial
Funder(s)
  • SantoSolve AS
Other Study ID Numbers
2PX-OA-03
Sponsor(s)
Smerud Medical Research International AS
Key Dates

Recruitment Start Date

Jun 2009

Recruitment End Date

May 2010

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date Assigned

06 Aug 2009

Last Updated

22 Mar 2010